RecruitingNot Applicable

Mindfulness-Based fMRI Neurofeedback for Depression

United States90 participantsStarted 2024-04-10

Plain-language summary

In the United States, adolescents experience alarmingly high rates of major depression, and gold-standard treatments are only effective for approximately half of patients. Rumination may be a promising treatment target, as it is well-characterized at the neural level and contributes to depression onset, maintenance, and recurrence as well as predicts treatment non-response. Accordingly, the proposed research will investigate whether an innovative mindfulness-based real-time functional magnetic resonance imaging (fMRI) neurofeedback intervention successfully elicits change in the brain circuit underlying rumination to improve clinical outcomes among depressed adolescents.

Who can participate

Age range13 Years – 18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Ages 13-18 years-old * Written informed assent/consent and parental/guardian permission for 13-17 year-olds or informed consent for 18 year-olds * Tanner puberty stage ≥3 * Meets current diagnostic criteria for MDD * English fluency Exclusion Criteria: * Lifetime history of primary psychotic disorders, bipolar disorder, oppositional defiant disorder, conduct disorder, developmental disorder (e.g., autism), post-traumatic stress disorder, or eating disorders * Substance use disorder, moderate or severe in past 6 months * Active suicidal ideation with a specific plan * History of seizure disorder * Medical or neurological illness (e.g., severe head injury) * MRI contraindications * Current psychotropic medication use other than antidepressant medication * Intelligence quotient (IQ) \<80.

What they're measuring

Within-person Default Mode Network (DMN) Connectivity

Timeframe: Pre-mbNF procedure

Within-person Default Mode Network (DMN) Connectivity

Timeframe: Post-mbNF procedure

Trial details

NCT IDNCT05617495

SponsorColumbia University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-01-31

Contact for this trial

Randy P Auerbach, PhD

646-774-5745 rpa2009@cumc.columbia.edu